Evaluation Summary:
There are mixed results from studies of COVID-19 outcomes in patients treated with statins and there are multiple confounders. The authors use two Mendelian randomization methods to explore the association between HMGCoA reductase inhibitors (statins) and other lipid lowering drugs and outcomes and find that increased expression of HMGCoA reductase and HMGCoA reductase mediated LDL cholesterol increase hospitalization risk. This makes it possible but does not prove that statins could improve outcomes which will be of broad interest.
(This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #1 and Reviewer #2 agreed to share their names with the authors.)
Reviewer #1 (Public Review):
Given that lipid metabolism plays an important role in viral infections, that lipid lowering drugs especially statins (HMGCoA reductase inhibitors) are widely used and that observational studies investigating the association between statin use and COVID-19 outcomes have given mixed results it's attractive to resort to mendelian randomization to minimize confounding and avoid reverse causation to address the potential benefits of lipid lowering drugs in this context.
The authors use selected target genes for three lipid lowering drug classes - HMGCoA reductase inhibitors (statins), PCSK9 inhibitors and the NPC1L1 inhibitor ( ezetimibe) ; large well characterized COVID GWAS case and control data sets; summary -data-based MR (SMR) and inverse variance weighted MR ( IVW-MR) and sensitivity analysis.
They demonstrate with SMR that a higher expression of HMGCR was associated with a higher risk of COVID-19 hospitalization. With IVW-MR they observed a positive association between HMGCR -mediated LDL cholesterol and COVID-19 hospitalization. For the other two drug classes no clear associations were shown.
This suggests but does not prove that HMGCR drugs ie statins might improve outcomes. For the other two classes its unclear if there would be sufficient users of these drugs in the data sets to provide enough power to adequately address the issue.
Overall this is a well conducted study providing important further insights but the final sentence of the abstract as well as the related discussion section including the limitations should be more expressed more conservatively.
Reviewer #2 (Public Review):
Lipid metabolism plays an important role in viral infection. The study aimed to assess a putative causal effect of lipid-lowering drugs including HMGCR inhibitors, PCSK9 inhibitors and NPC1L1 inhibitors on COVID-19 outcomes.
Two kinds of genetic instruments to proxy the exposure of lipid-lowering drugs, including eQTLs of drugs target genes, and genetic variants within or nearby drugs target genes associated with LDL cholesterol from GWAS were used. Mendelian randomisation analysis was performed. A higher expression of HMGCR was associated with a higher risk of COVID-19 hospitalisation (OR=1.38, 95%CI=1.06-1.81) at suggestive significance. Similarly, a positive association between HMGCR-mediated LDL cholesterol and COVID-19 hospitalisation (OR=1.32, 95%CI=1.00-1.74) was also observed.
The authors conclude a potential causal evidence that HMGCR inhibitors could reduce the risk of COVID-19 hospitalisation, providing insights into the prevention and management of COVID19 infection.
